Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
226.6 USD | +2.74% | +3.51% | +10.32% |
May. 30 | Transcript : Cencora, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-30-2024 09:20 AM | |
May. 29 | Baird Adjusts Price Target on Cencora to $280 From $277 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.16 times its sales.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.32% | 44.62B | B- | ||
-7.16% | 178B | C+ | ||
-4.86% | 67.04B | A | ||
-4.28% | 47.24B | B- | ||
+8.14% | 42.5B | B+ | ||
+15.76% | 29.99B | B | ||
+15.53% | 25.22B | A- | ||
-5.88% | 24.14B | A- | ||
-5.38% | 23.69B | B | ||
+1.38% | 22.04B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COR Stock
- Ratings Cencora, Inc.